Published April 7, 2022 By Vanessa Doctor, RN BioSpace Shares in Acadia Pharmaceuticals rose 5.71% to $27.22 per share at the close of NASDAQ Wednesday on positive late-stage data from the study […]
Boehringer Ingelheim announced the company’s intention to pump €25 billion ($27 billion) into its R&D pipeline over the next five years.
In the summer of 2021, over 200 biopharma executives were surveyed about their changing approaches to building biologic drug development pipelines. This executive summary presents the findings from this outreach.
The world’s leading COVID-19 vaccine and therapeutic manufacturers continue to develop treatments for the waves of variants as well as life-changing therapies for disease areas outside the world of coronaviruses. The world’s efforts to combat the global pandemic continue to evolve, as does Coronavirus Disease 2019 as variants and subvariants constantly toss volleys of grenades at the battlefront lines.
Temps are falling and so is investor cash as BioSpace reviewed which biotech companies are scooping up the dollars.
Eli Lilly acquired exclusive rights to a technology from Canada-based Entos Pharmaceuticals that the Indianapolis-based company believes will boost the development of nucleic acid therapeutics that target the central and peripheral nervous systems.
Paris-based Sanofi is buying South San Francisco’s Amunix Pharmaceuticals in a deal topping $1.225 billion.
Although the endocannabinoid system has been intensely studied, there are still few drugs approved or in development that interact with it.
GlaxoSmithKline Plc and U.S. firm Alector Inc. will together develop antibody-based treatments for Parkinson’s, Alzheimer’s and other similar diseases in a deal worth up to $2.2 billion, the drugmakers said on July 2.
Med Ad News talked to Wendbush Securities analysts David Nierengarten, Laura Chico, and Liana Moussatos about various new drug approvals and other recent news updates in the industry.